Bradmer Pharmaceuticals (TSE:GLX – Get Free Report) was upgraded by stock analysts at Benchmark to a “strong-buy” rating in a research report issued to clients and investors on Monday,Zacks.com reports.
Separately, Cantor Fitzgerald raised Bradmer Pharmaceuticals to a “strong-buy” rating in a report on Tuesday, February 25th.
Read Our Latest Stock Report on Bradmer Pharmaceuticals
Bradmer Pharmaceuticals Stock Performance
Featured Articles
- Five stocks we like better than Bradmer Pharmaceuticals
- Stock Trading Terms – Stock Terms Every Investor Needs to Know
- First Watch Restaurant Group: A First-Rate Small-Cap Growth Stock
- Following Congress Stock Trades
- Rocket Lab: $5.6 Billion Defense Contract Fuels RKLB’s Future
- What Are the U.K. Market Holidays? How to Invest and Trade
- 5 Reasons the S&P 500 Could Rebound Strongly in 2025
Receive News & Ratings for Bradmer Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bradmer Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
